Universal Beteiligungs und Servicegesellschaft mbH Has $23.87 Million Stock Position in ResMed Inc. $RMD

Universal Beteiligungs und Servicegesellschaft mbH cut its holdings in ResMed Inc. (NYSE:RMD) by 3.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 92,535 shares of the medical equipment provider’s stock after selling 3,339 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.06% of ResMed worth $23,874,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in RMD. Integrated Quantitative Investments LLC acquired a new stake in ResMed in the 2nd quarter valued at $1,019,000. Citizens Financial Group Inc. RI grew its holdings in shares of ResMed by 24.0% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 1,125 shares of the medical equipment provider’s stock valued at $290,000 after acquiring an additional 218 shares in the last quarter. Ontario Teachers Pension Plan Board acquired a new stake in shares of ResMed in the second quarter valued at about $389,000. Intech Investment Management LLC raised its holdings in ResMed by 45.0% during the second quarter. Intech Investment Management LLC now owns 22,216 shares of the medical equipment provider’s stock worth $5,732,000 after acquiring an additional 6,891 shares in the last quarter. Finally, Creative Planning raised its holdings in ResMed by 5.9% during the second quarter. Creative Planning now owns 31,705 shares of the medical equipment provider’s stock worth $8,180,000 after acquiring an additional 1,765 shares in the last quarter. Institutional investors own 54.98% of the company’s stock.

ResMed Trading Up 0.7%

RMD stock opened at $246.38 on Wednesday. ResMed Inc. has a one year low of $199.92 and a one year high of $293.81. The stock has a market cap of $35.96 billion, a price-to-earnings ratio of 25.91, a price-to-earnings-growth ratio of 1.75 and a beta of 0.87. The company has a fifty day moving average price of $264.92 and a two-hundred day moving average price of $263.27. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.44 and a quick ratio of 2.53.

ResMed (NYSE:RMD) last posted its earnings results on Friday, October 31st. The medical equipment provider reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The company had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.33 billion. ResMed had a net margin of 27.22% and a return on equity of 25.62%. ResMed’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.20 EPS. Equities analysts anticipate that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Thursday, November 13th will be given a dividend of $0.60 per share. The ex-dividend date is Thursday, November 13th. This represents a $2.40 annualized dividend and a yield of 1.0%. ResMed’s dividend payout ratio (DPR) is 24.56%.

Insider Transactions at ResMed

In related news, General Counsel Michael J. Rider sold 100 shares of ResMed stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $274.36, for a total transaction of $27,436.00. Following the completion of the sale, the general counsel directly owned 11,327 shares of the company’s stock, valued at approximately $3,107,675.72. This trade represents a 0.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $252.05, for a total value of $504,100.00. Following the completion of the sale, the director owned 66,110 shares of the company’s stock, valued at $16,663,025.50. This trade represents a 2.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 18,607 shares of company stock worth $4,919,501. Insiders own 0.65% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on RMD shares. CLSA raised ResMed from a “hold” rating to an “outperform” rating in a research report on Tuesday, September 2nd. Stifel Nicolaus boosted their target price on shares of ResMed from $240.00 to $270.00 and gave the stock a “hold” rating in a report on Friday, August 1st. UBS Group upgraded shares of ResMed to a “strong-buy” rating in a research note on Tuesday, September 16th. William Blair raised shares of ResMed to a “strong-buy” rating in a research report on Friday, August 1st. Finally, Royal Bank Of Canada upped their target price on shares of ResMed from $300.00 to $303.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $297.45.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.